June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Real life long term outcomes of patients receiving intra-vitreal Aflibercept for Neo-vascular age related macular degeneration (nAMD): three years follow up.
Author Affiliations & Notes
  • Yewande Babalola
    Sunderland Eye Infirmary, Stockton on Tees, United Kingdom
  • Lyudmila Kishikova
    Sunderland Eye Infirmary, Stockton on Tees, United Kingdom
  • Maged S Habib
    Sunderland Eye Infirmary, Stockton on Tees, United Kingdom
  • Deepali Varma
    Sunderland Eye Infirmary, Stockton on Tees, United Kingdom
  • Jonathan Smith
    Sunderland Eye Infirmary, Stockton on Tees, United Kingdom
  • Maria T Sandinha
    Sunderland Eye Infirmary, Stockton on Tees, United Kingdom
  • David Steel
    Sunderland Eye Infirmary, Stockton on Tees, United Kingdom
  • Ajay Kotagiri
    Sunderland Eye Infirmary, Stockton on Tees, United Kingdom
  • Footnotes
    Commercial Relationships   Yewande Babalola, None; Lyudmila Kishikova, None; Maged Habib, Bayer (R), Novartis (R); Deepali Varma, bayer (R), novartis (R); Jonathan Smith, Bayer (R), Novartis (R); Maria Sandinha, Bayer (R); David Steel, Bayer (R), Novartis (R); Ajay Kotagiri, Bayer (R)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 423. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Yewande Babalola, Lyudmila Kishikova, Maged S Habib, Deepali Varma, Jonathan Smith, Maria T Sandinha, David Steel, Ajay Kotagiri; Real life long term outcomes of patients receiving intra-vitreal Aflibercept for Neo-vascular age related macular degeneration (nAMD): three years follow up.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):423.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Multi-centre trials have demonstrated the efficacy of Aflibercept in the management of nAMD. There is no long term real life data available, on patient’s outcomes 3 years after the initiation of treatment. We carried out a retrospective study of visual and anatomical outcomes 3 years after initiating Aflibercept therapy.

Methods : Retrospective analysis of 100 consecutive treatment naive eyes receiving intravitreal Aflibercept for the treatment of nAMD (April 2013-Nov 2016), at a single specialised ophthalmic centre in the north east of England, UK. In the first year, fixed dosing regimen was adhered to, with three monthly loading doses and a bimonthly regimen thereafter. Pro re nata (PRN) dosing regimen was followed after the first year. Visual acuity, OCT features, follow-up period and number of treatments received were noted.

Results : One hundred eyes (96 patients) receiving Aflibercept treatment for nAMD were included. Mean age at presentation was 79.6 years with 60% diagnosed as Occult choroidal neo-vascular membrane. Mean follow up period was 142.9wks (48.4-174.4wks). Ten patients (10 eyes) had died at the time of this analysis. Seven eyes were switched to Ranibizumab. Stability of vision was achieved by 82% of patients with 12% of patients gaining >15letters. 79% of patients maintained the vision they attained at 12months. On average, patients received 11 injections. 66% of OCT’s were noted to be dry at last follow up.

Conclusions : The real life outcomes confirm the long term effectiveness of Aflibercept in the treatment of nAMD after three years of treatment.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×